Literature DB >> 16103746

VSGP/F-spondin: a new ovarian cancer marker.

Ruth A Pyle-Chenault1, John A Stolk, David A Molesh, Dianne Boyle-Harlan, Patricia D McNeill, Elizabeth A Repasky, Zhong Jiang, Gary R Fanger, Jiangchun Xu.   

Abstract

The discovery of genes that are overexpressed in ovarian cancers provides valuable insight into ovarian cancer biology and will lead to the development of more effective treatment strategies for combating this disease. To identify genes exhibiting ovarian- and ovarian cancer-specific expression, we generated four subtracted cDNA libraries from primary and metastatic ovarian adenocarcinoma tissues. 3,400 cDNA clones from these libraries were analyzed by microarray for tissue distribution and tumor specificity using 32 pairs of fluorophore-labeled cDNA samples from a variety of normal tissues and ovarian tumor tissues. cDNA clones showing elevated expression in ovarian tumors were identified by DNA sequencing with comparison to public databases, and the most promising candidates were further analyzed by quantitative real-time polymerase chain reaction and Northern blot. This systematic approach led to the identification of a number of genes including vascular smooth muscle growth-promoting factor (VSGP/F-spondin), a secreted protein previously identified and cloned from bovine and human ovary. VSGP/F-spondin protein was observed in ovarian carcinomas but not in normal ovarian epithelium by immunohistochemistry with a VSGP/F-spondin antibody. The expression profile of VSGP/F-spondin identifies this molecule as a potential diagnostic marker or target for developing therapeutic strategies to treat ovarian carcinoma. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103746     DOI: 10.1159/000087379

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  11 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

2.  Experimental validation of 5 in-silico predicted glioma biomarkers.

Authors:  Rheal A Towner; Randy L Jensen; Brian Vaillant; Howard Colman; Debra Saunders; Cory B Giles; Jonathan D Wren
Journal:  Neuro Oncol       Date:  2013-10-24       Impact factor: 12.300

3.  Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.

Authors:  Suhaida A Selamat; Brian S Chung; Luc Girard; Wei Zhang; Ying Zhang; Mihaela Campan; Kimberly D Siegmund; Michael N Koss; Jeffrey A Hagen; Wan L Lam; Stephen Lam; Adi F Gazdar; Ite A Laird-Offringa
Journal:  Genome Res       Date:  2012-05-21       Impact factor: 9.043

4.  Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.

Authors:  Ben Davidson; Helene Tuft Stavnes; Arild Holth; Xu Chen; Yanqin Yang; Ie-Ming Shih; Tian-Li Wang
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

5.  A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma.

Authors:  Jin Song; Shannath L Merbs; Lori J Sokoll; Daniel W Chan; Zhen Zhang
Journal:  Clin Proteomics       Date:  2019-03-05       Impact factor: 3.988

Review 6.  Blood Biomarkers of Uveal Melanoma: Current Perspectives.

Authors:  Manuel F Bande Rodríguez; Beatriz Fernandez Marta; Nerea Lago Baameiro; Maria Santiago-Varela; Paula Silva-Rodríguez; María Jose Blanco-Teijeiro; Maria Pardo Perez; Antonio Piñeiro Ces
Journal:  Clin Ophthalmol       Date:  2020-01-20

7.  Ensemble of gene signatures identifies novel biomarkers in colorectal cancer activated through PPARγ and TNFα signaling.

Authors:  Stefano Maria Pagnotta; Carmelo Laudanna; Massimo Pancione; Lina Sabatino; Carolina Votino; Andrea Remo; Luigi Cerulo; Pietro Zoppoli; Erminia Manfrin; Vittorio Colantuoni; Michele Ceccarelli
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

8.  Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study.

Authors:  Katarzyna Marta Lisowska; Magdalena Olbryt; Volha Dudaladava; Jolanta Pamuła-Piłat; Katarzyna Kujawa; Ewa Grzybowska; Michał Jarząb; Sebastian Student; Iwona Krystyna Rzepecka; Barbara Jarząb; Jolanta Kupryjańczyk
Journal:  Front Oncol       Date:  2014-01-28       Impact factor: 6.244

9.  PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors.

Authors:  Kaixuan Shi; Xia Yin; Mei-Chun Cai; Ying Yan; Chenqiang Jia; Pengfei Ma; Shengzhe Zhang; Zhenfeng Zhang; Zhenyu Gu; Meiying Zhang; Wen Di; Guanglei Zhuang
Journal:  Elife       Date:  2019-05-03       Impact factor: 8.140

10.  Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells.

Authors:  Saya Nagasawa; Kazuhiro Ikeda; Daisuke Shintani; Chiujung Yang; Satoru Takeda; Kosei Hasegawa; Kuniko Horie; Satoshi Inoue
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.